Verano Holdings (VRNO) Interest Expenses (2021 - 2026)
Verano Holdings' (VRNO) quarterly Interest Expenses came in at $149.9 million in Q1 2026, up 126.18% year-on-year from $66.3 million in Q1 2025, and up 559.3% on a QoQ basis from -$32.6 million in Q4 2025.
Verano Holdings (VRNO) Interest Expenses (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Interest Expenses data on file, last reported at $149.9 million in Q1 2026.
- On a quarterly basis, Interest Expenses rose 126.18% year-over-year to $149.9 million in Q1 2026; TTM through Mar 2026 was $149.9 million, a 126.18% increase from a year earlier, with the FY2025 full-year figure at $289.7 million, up 451.18% from the prior year.
- Interest Expenses for Q1 2026 stood at $149.9 million, up from -$32.6 million in the prior quarter.
- Over the last five years, Interest Expenses for VRNO reached as high as $160.4 million in Q2 2025 and fell as low as -$32.6 million in Q4 2025.
- Historically, Interest Expenses has averaged $66.7 million across 5 years, with a median of $90.3 million in 2024.
- Across the five-year window, Interest Expenses soared 806.81% in 2023 and slumped 356.37% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $16.3 million in 2022, then decreased by 10.03% to $14.7 million in 2023, then declined by 13.47% to $12.7 million in 2024, then slumped by 356.37% to -$32.6 million in 2025, then soared by 559.3% to $149.9 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $149.9 million in Q1 2026, -$32.6 million in Q4 2025, and $66.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 1.77 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Verano Holdings | 1.99 Bn | 1.92 Bn | 98.98 Mn | 149.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.86 Mn |
| Mar 31, 2026 | 149.86 Mn |
| Dec 31, 2025 | -32.63 Mn |
| Dec 31, 2025 | -32.63 Mn |
| Sep 30, 2025 | 66.26 Mn |
| Sep 30, 2025 | 66.26 Mn |
| Jun 30, 2025 | 160.44 Mn |
| Jun 30, 2025 | 160.44 Mn |
| Mar 31, 2025 | 66.26 Mn |
| Mar 31, 2025 | 66.26 Mn |
| Dec 31, 2024 | 12.73 Mn |
| Dec 31, 2024 | 12.73 Mn |
| Sep 30, 2024 | 92.34 Mn |
| Sep 30, 2024 | 92.34 Mn |
| Jun 30, 2024 | 90.34 Mn |
| Jun 30, 2024 | 90.34 Mn |
| Mar 31, 2024 | 90.34 Mn |
| Mar 31, 2024 | 90.34 Mn |
| Dec 31, 2023 | 14.71 Mn |
| Dec 31, 2023 | 14.71 Mn |